Allarity Capital Surpluse vs Total Stockholder Equity Analysis

ALLR Stock

USD 1.26 0.07 5.88%

Allarity Therapeutics financial indicator trend analysis is way more than just evaluating Allarity Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Allarity Therapeutics is a good investment. Please check the relationship between Allarity Therapeutics Capital Surpluse and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allarity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allarity Stock, please use our How to Invest in Allarity Therapeutics guide.

Capital Surpluse vs Total Stockholder Equity

Capital Surpluse vs Total Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Allarity Therapeutics Capital Surpluse account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.

The correlation between Allarity Therapeutics' Capital Surpluse and Total Stockholder Equity is 0.77. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Allarity Therapeutics, assuming nothing else is changed. The correlation between historical values of Allarity Therapeutics' Capital Surpluse and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Allarity Therapeutics are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Capital Surpluse i.e., Allarity Therapeutics' Capital Surpluse and Total Stockholder Equity go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Capital Surpluse

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most indicators from Allarity Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Allarity Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allarity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Allarity Stock, please use our How to Invest in Allarity Therapeutics guide.As of 11/22/2024, Issuance Of Capital Stock is likely to grow to about 18.6 M, while Tax Provision is likely to drop (318.1 K).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	106K	60K	30K	46.9K
Total Operating Expenses	26.6M	16.9M	17.9M	17.8M

Reconciled Depreciation Total Operating Expenses

Allarity Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Inventory	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Other Liab	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Total Liab	Net Invested Capital
Other Current Liab		0.23	0.31	-0.02	-0.43	-0.06	0.08	-0.03	0.78	-0.03	-0.46	0.22	0.68	-0.36	0.18	-0.1	-0.89	0.85	0.28	0.85	-0.12	0.69	-0.08	-0.38	0.8	0.16
Total Current Liabilities	0.23		-0.72	-0.33	0.71	0.71	-0.16	-0.04	0.65	0.4	-0.35	0.16	0.15	-0.11	-0.06	-0.11	-0.33	0.32	-0.03	0.32	0.02	0.25	-0.11	-0.05	0.35	-0.07
Net Tangible Assets	0.31	-0.72		0.12	-0.71	-0.59	0.31	-0.11	-0.21	-0.46	-0.34	0.14	-0.03	0.01	-0.04	-0.01	0.0	0.0	-0.04	0.0	0.01	0.01	-0.02	0.03	0.02	-0.04
Retained Earnings	-0.02	-0.33	0.12		-0.54	0.28	0.68	-0.65	0.13	0.68	0.43	0.61	0.58	-0.55	0.91	0.91	0.02	-0.09	0.86	-0.09	-0.79	0.56	0.93	-0.67	-0.47	0.91
Accounts Payable	-0.43	0.71	-0.71	-0.54		0.53	-0.27	0.1	-0.05	0.09	-0.22	-0.1	-0.55	0.22	-0.48	-0.26	0.35	-0.32	-0.48	-0.32	0.39	-0.4	-0.28	0.38	-0.13	-0.47
Net Receivables	-0.06	0.71	-0.59	0.28	0.53		0.48	-0.68	0.46	0.81	-0.19	0.69	0.22	-0.44	0.37	0.58	0.09	-0.15	0.42	-0.15	-0.35	0.4	0.56	-0.39	-0.29	0.36
Inventory	0.08	-0.16	0.31	0.68	-0.27	0.48		-0.94	0.14	0.48	-0.21	0.93	0.26	-0.63	0.49	0.85	0.21	-0.3	0.57	-0.3	-0.46	0.53	0.82	-0.54	-0.47	0.47
Other Stockholder Equity	-0.03	-0.04	-0.11	-0.65	0.1	-0.68	-0.94		-0.19	-0.66	0.23	-0.96	-0.3	0.6	-0.54	-0.87	-0.25	0.35	-0.64	0.35	0.46	-0.48	-0.85	0.57	0.52	-0.52
Total Current Assets	0.78	0.65	-0.21	0.13	-0.05	0.46	0.14	-0.19		0.42	-0.35	0.4	0.72	-0.35	0.39	0.14	-0.82	0.79	0.41	0.79	-0.46	0.83	0.15	-0.38	0.6	0.38
Common Stock	-0.03	0.4	-0.46	0.68	0.09	0.81	0.48	-0.66	0.42		0.2	0.65	0.56	-0.55	0.81	0.8	-0.01	-0.06	0.8	-0.06	-0.63	0.49	0.81	-0.67	-0.38	0.81
Property Plant Equipment	-0.46	-0.35	-0.34	0.43	-0.22	-0.19	-0.21	0.23	-0.35	0.2		-0.37	0.15	-0.04	0.37	0.23	0.12	-0.13	0.31	-0.13	-0.21	-0.1	0.26	-0.2	-0.29	0.38
Other Liab	0.22	0.16	0.14	0.61	-0.1	0.69	0.93	-0.96	0.4	0.65	-0.37		0.37	-0.63	0.55	0.81	0.06	-0.15	0.61	-0.15	-0.52	0.62	0.79	-0.57	-0.35	0.53
Total Assets	0.68	0.15	-0.03	0.58	-0.55	0.22	0.26	-0.3	0.72	0.56	0.15	0.37		-0.56	0.78	0.45	-0.72	0.66	0.84	0.66	-0.59	0.82	0.49	-0.76	0.36	0.77
Short Long Term Debt Total	-0.36	-0.11	0.01	-0.55	0.22	-0.44	-0.63	0.6	-0.35	-0.55	-0.04	-0.63	-0.56		-0.54	-0.66	0.23	-0.08	-0.7	-0.08	0.16	-0.63	-0.66	0.92	0.04	-0.5
Total Stockholder Equity	0.18	-0.06	-0.04	0.91	-0.48	0.37	0.49	-0.54	0.39	0.81	0.37	0.55	0.78	-0.54		0.81	-0.23	0.17	0.94	0.17	-0.82	0.63	0.84	-0.75	-0.25	1.0
Property Plant And Equipment Net	-0.1	-0.11	-0.01	0.91	-0.26	0.58	0.85	-0.87	0.14	0.8	0.23	0.81	0.45	-0.66	0.81		0.2	-0.29	0.82	-0.29	-0.67	0.53	1.0	-0.7	-0.6	0.8
Net Debt	-0.89	-0.33	0.0	0.02	0.35	0.09	0.21	-0.25	-0.82	-0.01	0.12	0.06	-0.72	0.23	-0.23	0.2		-0.99	-0.25	-0.99	0.21	-0.67	0.17	0.31	-0.88	-0.22
Cash	0.85	0.32	0.0	-0.09	-0.32	-0.15	-0.3	0.35	0.79	-0.06	-0.13	-0.15	0.66	-0.08	0.17	-0.29	-0.99		0.16	1.0	-0.22	0.6	-0.26	-0.17	0.9	0.16
Non Current Assets Total	0.28	-0.03	-0.04	0.86	-0.48	0.42	0.57	-0.64	0.41	0.8	0.31	0.61	0.84	-0.7	0.94	0.82	-0.25	0.16		0.16	-0.66	0.68	0.85	-0.89	-0.18	0.93
Cash And Short Term Investments	0.85	0.32	0.0	-0.09	-0.32	-0.15	-0.3	0.35	0.79	-0.06	-0.13	-0.15	0.66	-0.08	0.17	-0.29	-0.99	1.0	0.16		-0.22	0.6	-0.26	-0.17	0.9	0.16
Common Stock Shares Outstanding	-0.12	0.02	0.01	-0.79	0.39	-0.35	-0.46	0.46	-0.46	-0.63	-0.21	-0.52	-0.59	0.16	-0.82	-0.67	0.21	-0.22	-0.66	-0.22		-0.65	-0.69	0.31	0.21	-0.84
Non Current Liabilities Total	0.69	0.25	0.01	0.56	-0.4	0.4	0.53	-0.48	0.83	0.49	-0.1	0.62	0.82	-0.63	0.63	0.53	-0.67	0.6	0.68	0.6	-0.65		0.54	-0.64	0.34	0.61
Capital Lease Obligations	-0.08	-0.11	-0.02	0.93	-0.28	0.56	0.82	-0.85	0.15	0.81	0.26	0.79	0.49	-0.66	0.84	1.0	0.17	-0.26	0.85	-0.26	-0.69	0.54		-0.72	-0.58	0.83
Other Current Assets	-0.38	-0.05	0.03	-0.67	0.38	-0.39	-0.54	0.57	-0.38	-0.67	-0.2	-0.57	-0.76	0.92	-0.75	-0.7	0.31	-0.17	-0.89	-0.17	0.31	-0.64	-0.72		0.04	-0.71
Total Liab	0.8	0.35	0.02	-0.47	-0.13	-0.29	-0.47	0.52	0.6	-0.38	-0.29	-0.35	0.36	0.04	-0.25	-0.6	-0.88	0.9	-0.18	0.9	0.21	0.34	-0.58	0.04		-0.27
Net Invested Capital	0.16	-0.07	-0.04	0.91	-0.47	0.36	0.47	-0.52	0.38	0.81	0.38	0.53	0.77	-0.5	1.0	0.8	-0.22	0.16	0.93	0.16	-0.84	0.61	0.83	-0.71	-0.27

Click cells to compare fundamentals

Allarity Therapeutics Account Relationship Matchups

Allarity Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	1.9M	1.8M	19.8M	2.3M	4.4M	6.5M
Total Current Liabilities	4.7M	5.5M	20.7M	11.2M	14.2M	11.7M
Net Tangible Assets	(32.1M)	(15.1M)	(10.0M)	(7.7M)	(8.8M)	(9.2M)
Retained Earnings	(32.4M)	(37.4M)	(66.5M)	(82.6M)	(94.5M)	(99.2M)
Accounts Payable	2.2M	2.1M	698K	6.3M	8.4M	5.5M
Net Receivables	1.7M	1.1M	1.3M	871K	946K	898.7K
Other Stockholder Equity	50.6M	62.5M	84.4M	83.2M	90.4M	58.3M
Total Current Assets	3.3M	1.7M	21.1M	5.0M	2.0M	1.9M
Common Stock	924K	1.6M	810K	2K	1.8K	1.7K
Property Plant Equipment	2.9M	2.1M	94K	21K	18.9K	18.0K
Other Liab	6.1M	2.3M	9.1M	349K	314.1K	298.4K

Pair Trading with Allarity Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allarity Stock

0.9

VALN

Valneva SE ADR Downward Rally

Pair Corr

Moving against Allarity Stock

0.66	KZR	Kezar Life Sciences	Pair Corr
0.6	MLYS	Mineralys Therapeutics, Downward Rally	Pair Corr

The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.

The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Allarity Stock Analysis

When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC